Maze Therapeutics

press releases archive

The information in our press releases and presentations should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.

August 31, 2022
Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease
February 17, 2022
Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
February 24, 2022
Maze Therapeutics Announces Publication in Nature Describing a Novel Mechanism Linking Well-Established Genetic Drivers of ALS and FTD
February 10, 2022
Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease
January 31, 2022
Maze Therapeutics to Present Preclinical Data Highlighting MZE001 as a Potential Treatment for Pompe Disease at 2022 WORLD Symposium
recent

want to get a hold of a representative?

Jillian Connell
Maze Therapeutics
jconnell@mazetx.com

media inquires

Katie Engleman
1AB
katie@1abmedia.com

Contact Us
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Essential Cookies

These cookies are necessary for our website to function and for measurement purposes. Opt-out rights do not apply to these cookies.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Powered by  GDPR Cookie Compliance